Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.
Microsure BV recently secured €38 million (US$40 million) in a series B2 funding round that will allow it to finalize the development of its microsurgical robot, the Musa-3. The robot system is designed to give microsurgeons the precision, stability and control that are currently beyond human capabilities. “We want to make a super microsurgeon from every microsurgeon,” Sjaak Deckers, CEO of Microsure, told BioWorld.
Olink Holding AB likely has some euphoric investors following Thermo Fisher Scientific Inc.’s announcement of an agreement to acquire the proteomics company for $26 per share in cash. The price represents a premium of nearly 75% on its recent trading average and brings the deal’s value to a stunning $3.1 billion, with net cash of $143 million.
RSS
